UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
A solid budget helps young professionals manage irregular income and set aside funds for future goals.
19,770 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
A dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
Coinbase warns possible weekend disruptions as it schedules a brief system upgrade for Saturday. Traders should expec...
Amundi, Europe's biggest asset manager, launches a UCITS-compliant Solana fund in partnership with SPiko Finance, mar...
Retirees cling to a low-cost dividend ETF that advisors often push, yet most seniors can’t recall the ticker. This re...
Jaguar (JAGX) 2025 earnings show a company shifting from product-driven revenue to licensing cash. This piece breaks ...
A leading investment fund recently opened a sizable stake in STGW after marquee client wins. Here’s what this move co...
A rare stock market signal has flashed again, marking the ninth occurrence since 1950. Goldman Sachs says the readout...
AI infrastructure bets push a trillion-dollar spending agenda, yet water-use concerns from almond farming and local o...
Workday is set to report Q1 earnings after the close tonight, the first quarter under its returning CEO. Analysts foc...
As storms loom and costs climb, homeowners need more than a mortgage. This report examines resilience financing, insu...
A utilities-focused ETF has delivered defensive resilience through several recessions this century, as AI demand and ...